glp-1/glucagon dual receptor agonist Machine learning designs new GCGR/GLP-1R agonists with enhanced biological potency Trends in the Development of
Description
vomiting & diarrhea)
Clinicians should not discard a reduction in the GLP-1 RA dose upon a worsening of symptoms (Figure 4) [35]
These agents are likely to vary widely in their affinity and potency at each hormone receptor
Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study
PAM variants are also more common in people with diabetes
Follow him on X at @byjakeconley or email him at jake.co [email protected]
